Merin Noah M, Kelly Kevin R
Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.
Pharmaceuticals (Basel). 2014 Dec 24;8(1):1-20. doi: 10.3390/ph8010001.
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
多发性骨髓瘤（MM）是一种无法治愈的血液系统恶性肿瘤，其特征为肿瘤性浆细胞的克隆性增殖。蛋白酶体抑制剂用于MM治疗已使治疗结果有了显著改善。本文综述了两种已获批的蛋白酶体抑制剂（硼替佐米和卡非佐米）的使用数据，以及正在研发的新型药物。重点介绍了蛋白酶体抑制剂的临床应用，包括副作用的管理以及与其他药物的联合使用。
